Allogene Therapeutics ALLO Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Allogene Therapeutics’s reported figures.
Based on the most recent quarter.
The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Allogene Therapeutics's debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Allogene Therapeutics's debt-to-equity?
- Allogene Therapeutics (ALLO) reported debt-to-equity of 0.3× in Q1 2026.
- How has Allogene Therapeutics's debt-to-equity changed year-over-year?
- Allogene Therapeutics's debt-to-equity increased by 26.0% year-over-year, from 0.2× to 0.3×.
- What is the long-term trend for Allogene Therapeutics's debt-to-equity?
- Over 5 years (2020 to 2025), Allogene Therapeutics's debt-to-equity has grown at a 39.9% compound annual growth rate (CAGR), from 0.1× to 0.3×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.